Top

International Urogynecology Journal

Published in:

Open Access 01-10-2015 | Review Article

Refractory overactive bladder: a common problem?

Authors: Ulrich Schwantes, Joachim Grosse, Andreas Wiedemann

Published in: International Urogynecology Journal | Issue 10/2015

Abstract

Introduction and hypothesis

Unsatisfactory treatment outcome sometimes is described as frequently occurring in patients treated with first-line therapy for overactive bladder (OAB). The present article reviews the different circumstances which may result in failure to respond to lifestyle interventions, behavioral therapy, and/or antimuscarinic treatment.

Methods

An extensive literature search was conducted to identify relevant articles on pathophysiological, clinical, and pharmacological aspects of refractory OAB.

Results

Missing definition, unrealistic individual expectation of treatment outcomes, lack of communication between physician and patient as well as pathophysiological and pharmacological processes were identified as relevant for failure to respond to first-line OAB treatment. Increase of patient’s motivation to adhere to the prescribed treatment, critical examination of the patient in regard to the initial diagnosis, and individual adjustment of antimuscarinic therapy may be appropriate tools to improve treatment outcome in OAB patients.

Conclusions

Overall, the incidence of refractory OAB seems to be overestimated. There are several approaches to improve therapy results.

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463. doi:10.1016/j.juro.2012.09.079 CrossRefPubMed

Lucas MG, Bedretdinova D, Bosch JLHR, Burkhard F, Cruz F, Nambiar AK, Nilsson CG, De Ridder DJMK, Tubaro A, Pickard RS (2014) EAU guidelines on urinary incontinence. European Association of Urology. Available via http://www.uroweb.org/gls/pdf/20%20Urinary%20Incontinence_LR.pdf. Accessed 4 Sep 2014

Bosch JL, Groen J (2000) Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. J Urol 163(4):1219–1222CrossRefPubMed

Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT, Ntanios F (2014) Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Curr Med Res Opin 30(3):509–526. doi:10.1185/03007995.2013.860021 CrossRefPubMed

Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD (2009) Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 181(6):2608–2615. doi:10.1016/j.juro.2009.01.117 PubMedCentralCrossRefPubMed

Balachandran A, Curtiss N, Basu M, Duckett J (2015) Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy? Int Urogynecol J 26(3):367–372. doi:10.1007/s00192-014-2462-2 CrossRefPubMed

Nadeau G, Schröder A, Moore K, Genois L, Lamontagne P, Hamel M, Pellerin E, Bolduc S (2014) Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: long-term results of a prospective open-label study. Can Urol Assoc J 8(5–6):175–180. doi:10.5489/cuaj.1362 PubMedCentralPubMed

Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert K-D (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25(5):441–445CrossRefPubMed

Wong C, Duggan P (2009) Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. J Obstet Gynaecol 29(1):31–34. doi:10.1080/01443610802628726 CrossRefPubMed

10.

Kaplan SA, Cardozo L, Herschorn S, Grenabo L, Carlsson M, Arumi D, Crook TJ, Whelan L, Scholfield D, Ntanios F et al (2014) Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract 68(9):1065–1073. doi:10.1111/ijcp.12464 PubMedCentralCrossRefPubMed

11.

Swartz M, Vasavada S (2009) Diagnosing, treating refractory OAB. Renal and Urology News. Available via http://www.renalandurologynews.com/diagnosing-treating-refractory-oab/article/129979/. Accessed 3 Sep 2014

12.

Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105(9):1276–1282. doi:10.1111/j.1464-410X.2009.09036.x CrossRefPubMed

13.

Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30(7):1242–1248. doi:10.1002/nau.21054 PubMed

14.

Chughtai B, Dunphy C, Lee R, Lee D, Sheth S, Marks L, Kaplan SA, Te AE (2014) Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol 21(2):7217–7221PubMed

15.

Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE (2012) Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Int Urol Nephrol 44(1):91–97. doi:10.1007/s11255-011-9979-9 CrossRefPubMed

16.

Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM (2012) The management of overactive bladder syndrome. BMJ 344:e2365. doi:10.1136/bmj.e2365 CrossRefPubMed

17.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (12):CD005493. doi:10.1002/14651858.CD005493.pub3

18.

Herbison GP, Arnold EP (2009) Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev (2):CD004202. doi:10.1002/14651858.CD004202.pub2

19.

Maserejian NN, Wager CG, Giovannucci EL, Curto TM, McVary KT, McKinlay JB (2013) Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. Am J Epidemiol 177(12):1399–1410. doi:10.1093/aje/kws411 PubMedCentralCrossRefPubMed

20.

Hampel C (2007) Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6(5):432–437CrossRef

21.

Jundt K, Schreyer K, Friese K, Peschers U (2011) Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 284(3):663–666CrossRefPubMed

22.

Drake MJ (2012) Male lower urinary tract symptoms associated with overactive bladder. Can Urol Assoc J 6(5 Suppl 2):S136–S137. doi:10.5489/cuaj.12202 PubMedCentralPubMed

23.

Robinson D, Giarenis I, Cardozo L (2013) The medical management of refractory overactive bladder. Maturitas 74(4):386–390. doi:10.1016/j.maturitas.2013.01.012 CrossRefPubMed

24.

Digesu GA, Sadenghi P, Sharma S, Puccini F, Tubaro A, Fernando R, Khullar V (2013) The importance of cystoscopy and bladder biopsy in women with refractory overactive bladder: the urogynaecologist’s point of view? Eur J Obstet Gynecol Reprod Biol 169(2):408–411. doi:10.1016/j.ejogrb.2013.05.027 CrossRefPubMed

25.

Liu HT, Jiang YH, Kuo HC (2013) Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PLoS One 8(10):e76706. doi:10.1371/journal.pone.0076706 PubMedCentralCrossRefPubMed

26.

Liu HT, Lin H, Kuo HC (2011) Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 30(8):1525–1529. doi:10.1002/nau.21118 CrossRefPubMed

27.

Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar V (2013) Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J 24(9):1523–1528. doi:10.1007/s00192-012-2038-y CrossRefPubMed

28.

Malhotra B, Darsey E, Crownover P, Fang J, Glue P (2011) Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol 72(2):226–234. doi:10.1111/j.1365-2125.2011.03948.x PubMedCentralCrossRefPubMed

29.

Skerjanec A (2006) The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 45(4):325–350CrossRefPubMed

30.

Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35:515–520CrossRefPubMed

31.

Simon HU, Malhotra B (2009) The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 139(9–10):146–151, doi:smw-12542PubMed

32.

Wiedemann A, Schwantes PA (2007) Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same ? A comparative review of data pertaining to pharmacological and physiological aspects. Eur J Geriatr 9(Suppl1):29–42

33.

Geyer J, Gavrilova O, Petzinger E (2009) The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic OAB drug trospium chloride. Drug Metab Dispos 37(7):1371–1372CrossRefPubMed

34.

Bexten M, Oswald S, Grube M, Jia J, Graf T, Zimmermann U, Rodewald K, Zolk O, Schwantes U, Siegmund W, Keiser M (2015) Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm 12:171–178CrossRefPubMed

35.

Lukkari E, Castrèn-Kortekangas P, Juhakoski A, Löyttyniemi E, Aranko K, Neuvonen PJ (1996) Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur J Clin Pharmacol 50:221–223CrossRefPubMed

36.

Sahlmann J, Clasen N, Schwantes U, Rachor D, Neumeister C, Schulz H-U (2010) Bioavailability of trospium chloride (TC) immediate release (IR) compared with an extended release (ER) form under everyday conditions. Eur Urol Suppl 9(6):620CrossRef

37.

Malhotra BK, Wood N, Sachse R (2009) Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 47(9):570–578CrossRefPubMed

38.

Hughes KM, Lang JCT, Lazare R, Gordon D, Stanton SL, Malone-Lee JG, Geraint M (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22(7):859–869CrossRefPubMed

39.

Krauwinkel WJJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink MEJ (2005) Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 43(5):227–238CrossRefPubMed

40.

Wefer J, Truss MC, Jonas U (2001) Tolterodine: an overview. World J Urol 19(5):312–318CrossRefPubMed

41.

Doroshyenko O, Jetter A, Odenthal KP, Fuhr U (2005) Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 44(7):701–720CrossRefPubMed

42.

Kerbusch T, Wählby U, Milligan PA, Karlsson MO (2003) Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 56(6):639–652PubMedCentralCrossRefPubMed

43.

Lukkari E, Hakonen T, Neuvonen PJ (1998) The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 53:351–354CrossRefPubMed

44.

Guay DRP (1999) Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 19(3):267–280CrossRefPubMed

45.

Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843–853CrossRefPubMed

46.

Sumukadas D, McMurdo MET, Mangoni AA, Guthrie B (2014) Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age Ageing 43(4):515–521CrossRefPubMed

47.

Ancelin ML, Artero S, Portet F, Dupuy A-M, Touchon J, Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332:455–459PubMedCentralCrossRefPubMed

48.

Schneider T, Hein P, Michel-Reher MB, Michel MC (2005) Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn Schmiedebergs Arch Pharmacol 372(1):71–78CrossRefPubMed

49.

Chapple CR, Rosenberg MT, Brenes FJ (2009) Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 104(7):960–967CrossRefPubMed

50.

Amend B, Hennenlotter J, Schäfer T, Horstmann M, Stenzl A, Sievert K-D (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53(5):1021–1028CrossRefPubMed

51.

Kosilov K, Loparev S, Iwanowskaya M, Kosilova L (2014) Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent European J Urol 67(1):43–48. doi:10.5173/ceju.2014.01.art9 PubMedCentralPubMed

52.

Nardulli R, Losavio E, Ranieri M, Fiore P, Megna G, Bellomo RG, Cristella G, Megna M (2012) Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol 25(1 Suppl):35S–41SPubMed

53.

Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M (2009) Double anticholinergic therapy for refractory overactive bladder. J Urol 182(4 Suppl):2033–2038. doi:10.1016/j.juro.2009.05.099 CrossRefPubMed

54.

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A (2014) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. doi:10.1016/j.eururo.2014.02.012

55.

Diefenbach K, Donath F, Maurer A, Quispe-Bravo SDW, Schwantes U, Haselmann J, Roots I (2003) Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 23(6):395–404CrossRefPubMed

56.

Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I (2005) Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > 50 years. BJU Int 95(3):346–349CrossRefPubMed

57.

Kranz J, Petzinger E, Geyer J (2011) Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol 31:219–224PubMedCentralCrossRefPubMed

58.

Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, Oefelein MG (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64(9):1294–1300. doi:10.1111/j.1742-1241.2010.02433.x CrossRefPubMed

59.

Wadie BS (2014) Management of refractory OAB in the non-neurogenic patient. Curr Urol Rep 15(9):438. doi:10.1007/s11934-014-0438-x CrossRefPubMed

Title: Refractory overactive bladder: a common problem?
Authors: Ulrich Schwantes
Joachim Grosse
Andreas Wiedemann
Publication date: 01-10-2015
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 10/2015
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-015-2674-0

At a glance: The STEP trials

Springer Medicine

Refractory overactive bladder: a common problem?

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Gold standard: a failed concept

Disclosures, conflict of interest, and funding issues in urogynecology articles: a bibliometric study

Successful use of ring pessary with support for advanced pelvic organ prolapse

Use of a vessel loop to ensure tunnel patency during LeFort colpocleisis

Ultrasonographic evaluation of urethrovesical junction mobility: correlation with type of delivery and stress urinary incontinence

The management of massive haematomas after insertion of retropubic mid-urethral slings